Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a

Journal of Medicinal Chemistry

Volumn 42, Issue 11, 1999, Pages 1965-1974

  Finch, Angela M ^a   Wong, Allan K ^a   Paczkowski, Natalii J ^a   Wadi, S Khémar ^a   Craik, David J ^a   Fairlie, David P ^a   Taylor, Stephen M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; AUTACOID; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT INHIBITOR; MACROCYCLIC COMPOUND; PEPTIDE; PLASMA PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR; COMPLEMENT INHIBITION; CYCLIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MOLECULAR WEIGHT; NEUTROPHIL; PEPTIDE SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RECEPTOR SENSITIVITY; STRUCTURE ACTIVITY RELATION; TEMPERATURE DEPENDENCE;

ANTIGENS, CD; COMPLEMENT C5A; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDES; PEPTIDES, CYCLIC; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033519733     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9806594     Document Type: Article

References (33)

1. Jose, P. J.; Moss, I. K.; Maini, R. N.; Williams, T. J. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. 1990, 49, 747-52.
2. Valazquez, P.; Cribbs, D. H.; Poulos, T. L.; Tenner, A. J. Aspartate residue 7 in amyloid beta protein is critical for classical complement pathway activation: implications for alzheimers disease pathogenesis. Nature Med. 1997 3, 77-9.
3. Engler, R. L.; Roth, D. M.; del Balzo, U.; Ito, B. R. Intracoronary C5a induces myocardial ischemia by mechanisms independent of the neutrophil: leukocyte filters desensitize the myocardium to C5a. FASEB J. 1991, 5, 2983-91.
4. Hammerschmidt, D. E.; Weaver, L. J.; Hudson, L. D.; Craddock, P. R.; Jacob, H. S. Association of complement activation and elevated plasma C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet 1980, 1, 947-9.
5. Mollison, K. W.; Mandecki, W.; Zuiderweg, E. R.; Fayer, L.; Fey, T. A.; Krause, R. A.; Conway, R. G.; Miller, L.; Edalji, R. P.; Shallcross, M. A.; et al. Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc. Natl. Acad. Sci. U.S.A 1989, 86, 292-6.
6. Bubeck, P.; Grotzinger, J.; Winkler, M.; Kohl, J.; Wollmer, A.; Klos, A.; Bautsch, W. Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor. Eur. J. Biochem. 1994, 219, 897-904.
7. Federwisch, M.; Wollmer, A.; Emde, M.; Stuhmer, T.; Melcher, T.; Klos, A.; Kohl, J.; Bautsch, W. Tryptophan mutants of human C5a anaphylatoxin: a fluorescence anisotropy decay and energy transfer study. Biophys. Chem. 1993, 46, 237-48.
8. Toth, M. J.; Huwyler, L.; Boyar, W. C.; Braunwalder, A. F.; Yarwood, D.; Hadala, J.; Haston, W. O.; Sills, M. A.; Seligmann, B.; Galakatos, N. The pharmacophore of the human C5a anaphylatoxin. Protein. Sci. 1994, 3, 1159-68.
9. Chenoweth, D. E.; Hugli, T. E. Human C5a and C5a analogues as probes of the neutrophil C5a receptor. Mol. Immunol. 1980, 17, 151-61.
10. Siciliano, S. J.; Rollins, T. E.; DeMartino, J.; Konteatis, Z.; Malkowitz, L.; VanRiper, G.; Bondy, S.; Rosen, H.; Springer, M. S. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 1214-8.
11. DeMartino, J. A.; Van Riper, G.; Siciliano, S. J.; Molineaux, C. J.; Konteatis, Z. D.; Rosen, H.; Springer, M. S. The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogues. J. Biol. Chem. 1994, 269, 14446-50.
12. Kawai, M.; Quincy, D. A.; Lane, B.; Mollison, K. W.; Luly, J. R.; Carter, G. W. Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J. Med. Chem. 1991, 34, 2068-71.
13. Kawai, M.; Quincy, D. A.; Lane, B.; Mollison, K. W.; Or, Y.-S.; Luly, J. R.; Carter, G. W. Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a. J. Med. Chem. 1992, 35, 220-3.
14. Mollison, K W.; Krause, R. A.; Fey, T. A.; Miller, L.; Wiedeman, P. E.; Kawai, M.; Lane, B.; Luly, J. R.; Carter, G. W. Hexapeptide analogues of C5a anaphylatoxin reveal heterogeneous neutrophil agonism/antagonism. FASEB J. 1992, 6, A2058.
15. Ember, J. A.; Sanderson, S. D.; Taylor, S. M.; Kawahara, M.; Hugli, T. E. Biologic activity of synthetic analogues of C5a anaphylatoxin. J. Immunol. 1992, 148, 3165-73.
16. Sanderson, S. D.; Ember, J. A.; Kirnarsky, L.; Sherman, S. A.; Finch, A. M.; Taylor, S. M. Decapeptide agonists of human C5a: the relationship between conformation and spasmogenic and platelet aggregatory activities. J. Med. Chem. 1994, 37, 3171-80.
17. Sanderson, S. D.; Kirnarsky, L.; Sherman, S. A.; Vogen, S. M.; Prakesh, O.; Ember, J. A.; Finch, A. M.; Taylor, S. M. Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response. J. Med. Chem. 1995, 38, 3669-75.
18. Finch, A. M.; Vogen, S. M.; Sherman, S. A.; Kirnarsky, L.; Taylor, S. M.; Sanderson, S. D. Biological active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. J. Med. Chem. 1997, 40, 877-84.
19. Drapeau, G.; Brochu, S.; Godin, D.; Levesque, L.; Rioux, F.; Marceau, F. Synthetic C5a receptor agonists. Pharmacology, metabolism and in vivo cardiovascular and hematologic effects. Biochem. Pharmacol. 1993, 45, 1289-99.
20. Konteatis, Z. D.; Siciliano, S. J.; Van Riper, G.; Molineaux, C. J.; Pandya, S.; Fischer, P.; Rosen, H.; Mumford, R. A.; Springer, M. S. Development of C5a receptor antagonists. Differential loss of functional responses. J. Immunol. 1994, 153, 4200-4.
21. Wong, A. K.; Finch, A. M.; Pierens, G. K.; Craik, D.; Taylor, S. M.; Fairlie, D. P. Molecular probes for G-protein coupled receptors. Conformationally constrained antagonists derived from the C-terminus of human plasma protein C5a. J. Med. Chem. 1998, 41, 3417-22.
22. Zhang, X.; Boyar, W.; Galakatos, N.; Gonnella, N. C. Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding. Protein Sci. 1997, 6, 65-72.
23. Pellas, T. C.; Boyar, W.; van Oostrum, J.; Wasvary, J.; Fryer, L. R.; Pastor, G.; Sills, M.; Braunwalder, A.; Yarwood, D. R.; Kramer, R.; Kimble, E.; Hadala, J.; Hasten, W.; Moreira-Ludewig, R.; Uziel-Fusi, S.; Peters, P.; Bill, K.; Wennogle, L. P. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo. J. Immunol. 1998, 160, 5616-21.
24. Kessler, H. Conformation and biological activity of cyclic peptides. Angew Chem., Int. Ed. 1982, 21, 512-23.
25. Dyson, H. J.; Wright, P. E. Defining solution conformations of small linear peptides. Annu. Rev. Biophys. Chem. 1991, 20, 519-38.
26. Rose, G. D.; Gierasch, L. M.; Smith, J. A. Turns in peptides and proteins. Adv. Protein Chem. 1988, 37, 1-109.
27. Short, A.; Wong, A. K.; Finch, A. M.; Haaima, G.; Shiels, I. A.; Fairlie, D. P.; Taylor, S. M. Effects of a new C5a receptor antagonist on C5a-and endotoxin-induced neutropenia in the rat. Br. J. Pharmacol. 1999, 126, 551-4.
28. Abbenante, G.; Fairlie, D. P.; Gahan, L. R.; Hanson, G. R.; Pierens, G. K.; van den Brenk, A. L. Conformational control by thiazole and oxazoline rings in cyclic octapeptidee of marine origin. Novel macrocyclic chair and boat conformations. J. Am. Chem. Soc. 1996, 118, 10384-8.
29. Pardi, A.; Billeter, M.; Wüthrich, K. Calibration of the angular dependence of the amide proton-C alpha proton coupling constants, 3JHN alpha, in a globular protein. Use of 3JHN alpha for identification of helical secondary structure. J. Mol. Biol. 1984, 180, 741-51.
30. Brünger, A. T. X-PLOR Manual Version 3.1; Yale University: New Haven, CT, 1992.
31. Nilges, M.; Gronenborn, A. M.; Brünger, A. T.; Clore, G. M. Determination of three-dimensional structures of proteins by simulated annealing with interproton distance restraints. Application to crambin, potato carboxypeptidase inhibitor and barley serine proteinase inhibitor 2. Protein Eng. 1988, 2, 27-38.
32. Clore, G. M.; Brünger, A. T.; Karplus, M.; Gronenborn, A. M. Application of molecular dynamics with interproton distance restraints to three-dimensional protein structure determination. A model study of crambin. J. Mol. Biol. 1986,191, 523-51.
33. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy minimization and dynamics calculations, J. Comput. Chem. 1983, 4, 187-217.